The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma

International Journal of Cancer

Volumn 75, Issue 4, 1998, Pages 649-653

  Prins, Jan Bas ^a,e   Williamson, Kathy A ^b,f   Kamp, Marga M K ^a   Van Hezik, Ed J ^c   Van Der Kwast, Theo H ^a   Hagemeijer, Anne ^d   Versnel, Marjan A ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c Ziekenhuis Walcheren   (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN;

ARTICLE; CHROMOSOME 1; CHROMOSOME 10; CHROMOSOME 6; CHROMOSOME 9P; CONTROLLED STUDY; CYTOGENETICS; GENE DELETION; GENE MAPPING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IN SITU HYBRIDIZATION; MESOTHELIOMA; RNA, MESSENGER; RNA, NEOPLASM;

EID: 0032498502     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980209)75:4<649::AID-IJC25>3.0.CO;2-2     Document Type: Article

References (23)

1. ALERS, J.C., KRIJTENBERG, P.J., VISSERS, K.J., BOSMAN, F.T., VAN DER KWAST, T.H. and VAN DEKKEN, H., Interphase cytogenetics of prostatic adenocareinomas and precursor lesions: analysis of 25 radical prostatectomies and 17 adjacent prostatic intra-epithelial neuplasias. Genes Chromosomes Cancer, 12, 241-250 (1995).
2. BJORKQVIST, A.-M., TAMMILEHTO, L., ANTTILA, S., MATTSON, K. and KNUUTILA, S., Recurrent DNA-copy-number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Brit. J. Cancer, 75, 523-527 (1997).
3. CAIRNS, P. and 20 OTHERS, Frequency of homozygous deletion at p16/ CDKN2 in primary human tumours. Nature Genet., 11, 210-212 (1995).
4. CENTER, R., LUKEIS, R., DIETZSCH, E., GILLESPIE, M. and GARSON, O.M., Molecular deletion of 9p sequences in non-small-cell lung cancer and malignant mesothelioma. Genes Chromosomes Cancer, 7, 47-53 (1993).
5. CHENG, J.Q., JHANWAR, S.C., KLEIN, W.M., BELL, D.W., LEE, W.C., ALTOMARE, D.A., NOBORI, T., OLOPADE, O.I., BUCKLER, A.J. and TESTA, J.R., p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res., 54, 5547-5551 (1994).
6. COLEMAN, A., FOUNTAIN, J.W., NOBORI, T., OLOPADE, O.I., ROBERTSON, G., HOUSMAN, D.E. and LUGO, T.G., Distinct deletions of chromosome 9p associated with melanoma versus glioma. lung cancer, and leukemia. Cancer Res., 54, 344-348 (1994).
7. COLLINS, A., FORABOSCO, P., LAWRENCE, S. and MORTON, N.E., An integrated map of chromosome 9. Ann. hum. Genet., 59, 393-402 (1995).
8. HAGEMEIJER, A., VERSNEL, M.A., VAN DRUNEN, E., MORET, M., BOUTS, M.J., VAN DER KWAST, T.H. and HOOGSTEDEN, H.C., Cytogenetic analysis of malignant mesothelioma. Cancer Genet. Cytogenet., 47, 1-28 (1990).
9. KAMB, A. and 23 OTHERS, Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet., 8, 23-26 (1994).
10. KERSTENS, H.M., PODDIGHE, P.J. and HANSELAAR, A.G., A novel in situ hybridization-signal-amplification method based on the deposition of biotinylated tyramine. J. Histochem. Cytochem., 43, 347-352 (1995).
11. LITTLE, M.H., WILLIAMSON, K.A., MANNENS, M., KELSEY, A., GOSDEN, C., HASTIE, N.D. and VAN HEYNINGEN, V., Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion. Hum. mol. Genet., 2, 259-264 (1993).
12. MANNING, L.S., WHITAKER, D., MURCH, A.R., GARLEPP, M.J., DAVIS, M.R., MUSK, A.W. and ROBINSON, B.W.S., Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int. J. Cancer, 47, 285-290 (1991).
13. MEDEMA, R.H., HERRERA, R.E., LAM, F. and WEINBERG, R.A., Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc. nat. Acad. Sci. (Wash.), 92, 6289-6293 (1995).
14. OKAMOTO, A., DEMETRICK, D.J., SPILLARE, E.A., HAGIWARA, K., PERWEZ HUSSAIN, S., BENNETT, W.P., FORRESTER, K., GERWIN, B., SERRANO, M., BHACH, D.H. and HARRIS, C.C., Mutations and altered expression of p16INK4 in human cancer. Proc. nat. Acad. Sci. (Wash.), 91, 11045-11049 (1994).
15. OLOPADE, O.I., POMYKALA, H.M., HAGOS, F., SVEEN, L.W., ESPINOSA III, R., DREYLING, M.H., GURSKY, S., STADLER, W.M., LE BEAU, M.M. and BOHLANDER, S.K., Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor-suppressor region on 9p21. Proc. nat. Acad. Sci. (Wash.), 92, 6489-6493 (1995).
16. POVEY, S., ARMOUR, J., FARNDON, P., HAINES, J.L., KNOWLES, M., OLOPADE, F., PILZ, A., WHITE, J.A. and KWIATKOWSKI, D.J., Report and abstracts of the Third International Workshop on Chromosome 9. Cambridge. United Kingdom, 9-11 April, 1994. Ann. hum. Genet., 58, 177-250 (1994).
17. SAMBROOK, J., FRITSCH, E.F. and MANIATIS, T., Molecular cloning. A laboratory manual (2nd ed.), Cold Spring Harbor Laboratory, New York (1989).
18. SERRANO, M., HANNON, G.J. and BEACH, D., A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366, 704-707 (1993).
19. SHIMIZU, E. and 12 OTHERS, RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small-cell carcinoma and mesothelioma. Oncogene, 9, 2441-2448 (1994).
20. TAGUCHI, T., JHANWAR, S.C., SIEGFRIED, J.M., KELLER, S.M. and TESTA, J.R., Recurrent deletions of specific chromosomal sites in 1p. 3p, 6q and 9p in human malignant mesothelioma. Cancer Res., 53, 4349-4355 (1993).
21. VERSNEL, M.A., HAGEMEIJER, A., BOUTS, M.J., VAN DER KWAST, T.H. and HOOGSTEDEN, H.C., Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant-mesothelioma cell lines derived from primary and metastatic tumors. Oncogene, 2, 601-605 (1988).
22. XIAO, S., LI, D., CORSON, J.M., VIJG, J. and FLETCHER, J.A., Co-deletion of p15 and p16 genes in primary non-small-cell lung carcinoma. Cancer Res., 55, 2968-2971 (1995).
23. ZHANG, S.Y., KLEIN-SZANTO, A.J., SAUTER, E.R., SHAFARENKO, M., MITSUNAGA, S., NOBORI, T., CARSON, D.A., RIDGE, J.A. and GOODROW, T.L., Higher frequency of alterations in the p16/CDKN2 gene in squamous-cell-carcinoma cell lines than in primary tumors of the head and neck. Cancer Res., 54, 5050-5053 (1994).